Academic Journal

The Promoting Resilience in Stress Management (PRISM) intervention for adolescents and young adults receiving hematopoietic cell transplantation: a randomized controlled trial protocol

التفاصيل البيبلوغرافية
العنوان: The Promoting Resilience in Stress Management (PRISM) intervention for adolescents and young adults receiving hematopoietic cell transplantation: a randomized controlled trial protocol
المؤلفون: Kaitlyn M. Fladeboe, Samantha Scott, Liam Comiskey, Chuan Zhou, Joyce P. Yi-Frazier, Abby R. Rosenberg
المصدر: BMC Palliative Care, Vol 21, Iss 1, Pp 1-9 (2022)
بيانات النشر: BMC, 2022.
سنة النشر: 2022
المجموعة: LCC:Special situations and conditions
مصطلحات موضوعية: AYA, Pediatrics, Childhood, Cancer, Hematopoietic cell transplant, Psychosocial outcomes, Special situations and conditions, RC952-1245
الوصف: Abstract Background Psychological distress is prevalent among adolescents and young adults (AYAs) receiving hematopoietic cell transplantation (HCT). The Promoting Resilience in Stress Management (PRISM) intervention is a resilience-coaching program that has been shown to mitigate distress and improve quality of life among AYAs receiving chemotherapy for newly diagnosed or advanced cancer. This article describes the protocol of an ongoing randomized-controlled trial (RCT) examining the efficacy of PRISM among AYAs receiving HCT for cancer and/or blood disorders. Methods/design The goal of this multi-site, parallel, RCT is to evaluate the effect of PRISM compared to psychosocial usual care (UC) among AYAs receiving HCT. Our primary hypothesis is that AYAs who receive PRISM will report lower depression and anxiety 6-months following enrollment compared to those who receive UC. The PRISM program includes four scripted coaching sessions targeting skills in stress-management, goal setting, cognitive-restructuring, and meaning-making, followed by a facilitated family meeting. Sessions are delivered one on one, 1–2 weeks apart, in-person or via videoconference. We aim to recruit 90 AYAs from 4 US pediatric AYA oncology centers. Eligible AYAs are aged 12–24 years; receiving HCT for malignancy or a bone marrow failure syndrome associated with cancer predisposition;
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1472-684X
Relation: https://doaj.org/toc/1472-684X
DOI: 10.1186/s12904-022-00966-9
URL الوصول: https://doaj.org/article/311ed9c656c74c16a3cff73a4c563987
رقم الانضمام: edsdoj.311ed9c656c74c16a3cff73a4c563987
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:1472684X
DOI:10.1186/s12904-022-00966-9